abies borisii-regis/sarcoma

Microdose administration of ABY-029, an anti-epidermal growth factor receptor Affibody molecule conjugated to IRDye 800CW, is being studied in a Phase 0 trial for resection of soft-tissue sarcomas. The excised tissue of a single patient in the microdose administration group was imaged with both a

Surgical excision via wide local excision (WLE) of the primary sarcoma tumor is a mainstay of treatment due to the limited effectiveness of chemotherapy and radiation. Even with attempts at WLE, 22-34% of the patient will be diagnosed with a positive margin by the pathologist, necessitating

Fluorescence-guided surgery using epidermal growth factor receptor (EGFR) targeting has been performed successfully in clinical trials using a variety of fluorescent agents. We investigate ABY-029 (anti-EGFR Affibody^® molecule labeled with

Chloroform (AGC), ethyl acetate (AGE) and n-butanol (AGB) extracts of Abies georgei were investigated for anti-tumour and anti-inflammatory activities in-vitro and in-vivo. AGC exhibited potent antiproliferative effects against A549, LOVO, QGY-7703 and 6T-CEM tumour cells, with EC50 values of 77.5,